



Press Release

Source: CLX Medical, Inc.

CLX Medical, Inc. Announces Agreement to Close Acquisition of the ThyroTest® Rapid Screening Device

Issued Thursday November 6, 1:16 pm ET

Agreement paves the way for cashless close expected within the next 10 days

MURRIETA, CA--(MARKET WIRE)--Nov. 6, 2008--CLX Medical, Inc. (OTC BB: CLXN), which is focused on the marketing and distribution of unique medical diagnostic testing products, today announced the signing of an amendment to its agreement to purchase the ThyroTest® product, which will allow CLX to close the acquisition through the issuance of preferred stock and a note in the amount of \$750,000.

ThyroTest® is a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease. CLX entered into a definitive agreement with ThyroTec, LLC, the developer of the ThyroTest® device, on September 8, 2008.

ThyroTest® is FDA cleared and has also achieved CLIA waived status, so the test can be administered in the more than 100,000 CLIA waived doctors' offices in the U.S., as well as in any non-waived laboratory.

Terms of the amendment to the definitive agreement include the issuance to ThyroTec of Series C Convertible Preferred Shares of CLX Medical and a note in the amount of \$750,000 at 6% interest for a term of 30 months, secured by the assets of the corporation. During the period of the note or until the principal is paid in full, CLX agrees to pay to ThyroTec a royalty of 10% of net sales of the ThyroTest® product.

An escrow will be established, into which the technology, the \$750,000 note and the 750,000 shares of Series C Preferred Shares will be deposited. The opening of the escrow will be considered the closing, which is expected to be completed by November 14, 2008.

“We are pleased to enter into this agreement, which allows CLX to close the acquisition of ThyroTest® without raising additional capital for the close,” commented Vera Leonard, chief executive officer of CLX Medical. “We look forward to a fast close under

the terms of this amended agreement, so we can move forward with the execution of our post-acquisition marketing and distribution plan for ThyroTest®.”

To sign up to receive information by email directly from CLX Medical, Inc. when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit <http://www.clxinvestments.com/email.php>.

About CLX Medical, Inc.

CLX Medical, Inc. (www.clxmedical.com) holds a 51% equity interest in Zonda, Inc. (www.zondaincusa.com), which has developed several rapid point of care tests for medical and non-medical markets, including a rapid test for chlamydia. CLX has also entered into a definitive agreement to acquire ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease. CLX Medical is focused on the successful worldwide distribution of these and any additional products it may acquire or license.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Medical, Inc. are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Medical’s control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact:

Gemini Financial Communications, Inc.

A. Beyer

951-677-8073

investors@clxmedical.com